Olin

OLN · NYSE

$15.15−$0.04 (−0.26%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $15.19

OLN analyst rating

HoldConsensus of 15 analysts over the last 12 months. 13% rate it a buy.

Strong buy0
Buy2
Hold11
Underperform2
Sell0

12-month price target · 18 analysts

Average $20.90 (+37.9% upside)

Low: $16.16
Now: $15.15
High: $27.30

Upgrades and downgrades

The latest rating actions, newest first

OLN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Truist Securities	Oct 20, 2026	Maintains	Hold	$20.00 → $15.00	43%
RBC Capital	Oct 13, 2026	Maintains	Sector Perform	$20.00 → $16.00	46%
Barclays	Oct 13, 2026	Initiates	Equal-Weight	$18.00	50%
UBS	Oct 5, 2026	Maintains	Neutral	$21.00 → $18.00	49%
Wells Fargo	Oct 1, 2026	Maintains	Equal-Weight	$20.00 → $16.00	33%
Citigroup	Sep 30, 2026	Maintains	Neutral	$19.00 → $17.00	53%
Citigroup	Sep 15, 2026	Initiates	Neutral	$19.00	53%
Keybanc	Sep 11, 2026	Initiates	Overweight	$26.00	30%
Deutsche Bank	Aug 25, 2026	Maintains	Hold	$30.00 → $20.00	64%
Goldman Sachs	Aug 4, 2026	Maintains	Neutral	$24.00 → $20.00	51%

The case for and against

Updated Jul 21, 2026

Bull case

Olin is a well-established company with a unique dual identity as the largest chlor-alkali producer and a leading ammunition manufacturer in the US. Despite some challenges such as production outages and supply chain disruptions, Olin's EBITDA and sales are expected to improve due to rising caustic soda prices in North America and strong demand in high-margin applications. While there are still risks to consider, such as competition and volatile input costs, Olin's disciplined approach to capacity expansion and focus on cost reduction should help support its financial performance and potential for long-term growth.

Bear case

Olin is facing several headwinds as it navigates a highly competitive market for its chlor-alkali products, with raw material costs remaining a significant concern. The company's "value over volume" commercial model for its core CAPV business may eventually support stronger earnings upside, but optimizing asset footprint and cost structure will be a multi-year process. Additionally, the company’s heavy turnaround schedule for 2026 and potential for intensified competition in the merchant chlorine market could continue to impact profitability. Despite the potential for a tighter caustic soda market, we do not see significant upside to the company's current valuation and maintain a Hold rating on the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.